Previous work in this field has shown that a germline deletion in BIM (BCL2L11), which alters RNA splicing and impairs the generation of the death-inducing isoform of BIM, is associated with resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, in lung cancer. This evidence concerns the gene EGFR and lung cancer.